Trials / Completed
CompletedNCT04910230
Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19
Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Qiang Hu · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The mechanism of peripheral blood lymphocyte decline in COVID-19 patients is not yet clear. However, one theory demonstrated that in the whole progression of COVID-19, the extensive activation of poly-ADP-ribose polymerase (PARP) may reduce the cellular NAD+ and dampen the adaptive immune system. So investigators presume that replenishing the NAD+ using nicotinamide as the precursor may improve the lymphocyte counts and boost the adaptive immune system. As a result, the study using nicotinamide as a kind of supportive therapy provide further evidence of their efficiency and safety in treating lymphopenia in patients with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nicotinamide | In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2020-04-02
- Completion
- 2020-04-02
- First posted
- 2021-06-02
- Last updated
- 2021-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04910230. Inclusion in this directory is not an endorsement.